Onsolis

Onsolis is a brand name of fentanyl, approved by the FDA in the following formulation(s):

ONSOLIS (fentanyl citrate - film; buccal)

• 
  Manufacturer: MEDA PHARMS
  
  Approval date: July 16, 2009
  
  Strength(s): EQ 0.2MG BASE, EQ 0.4MG BASE ^[RLD], EQ 0.6MG BASE, EQ 0.8MG BASE, EQ 1.2MG BASE
  

Has a generic version of Onsolis been approved?

No. There is currently no therapeutically equivalent version of Onsolis available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Onsolis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces
  Patent 6,159,498
  Issued: December 12, 2000
  Inventor(s): Tapolsky; Gilles H. & Osborne; David W.
  Assignee(s): Virotex Corporation
  The present invention relates to water-soluble, bioerodable pharmaceutical delivery device for application to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing drug delivery and protection to the treatment site.
  
  Patent expiration dates:
  
  
  • October 18, 2016
    
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
  Patent 7,579,019
  Issued: August 25, 2009
  Inventor(s): Tapolsky; Gilles H. & Osborne; David W.
  Assignee(s): Arius Two, Inc.
  The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.
  
  Patent expiration dates:
  
  
  • January 31, 2019
    
    ✓ 
    Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 16, 2012 - NEW PRODUCT
  
  

See also...

• Onsolis Consumer Information (Drugs.com)
• Onsolis Soluble Film Consumer Information (Wolters Kluwer)
• Onsolis buccal Consumer Information (Cerner Multum)
• Onsolis Advanced Consumer Information (Micromedex)
• Fentanyl Consumer Information (Drugs.com)
• Fentanyl Consumer Information (Wolters Kluwer)
• Fentanyl Lozenge Consumer Information (Wolters Kluwer)
• Fentanyl Patch Consumer Information (Wolters Kluwer)
• Fentanyl Soluble Film Consumer Information (Wolters Kluwer)
• Fentanyl Spray Consumer Information (Wolters Kluwer)
• Fentanyl Tablet Consumer Information (Wolters Kluwer)
• Fentanyl buccal Consumer Information (Cerner Multum)
• Fentanyl citrate oral transmucosal Consumer Information (Cerner Multum)
• Fentanyl nasal Consumer Information (Cerner Multum)
• Fentanyl sublingual Consumer Information (Cerner Multum)
• Fentanyl transdermal device Consumer Information (Cerner Multum)
• Fentanyl transdermal skin patch Consumer Information (Cerner Multum)
• Fentanyl Buccal mucosa, Oromucosal Advanced Consumer Information (Micromedex)
• Fentanyl Nasal Advanced Consumer Information (Micromedex)
• Fentanyl Transdermal Advanced Consumer Information (Micromedex)
• Fentanyl Citrate AHFS DI Monographs (ASHP)